Related Experiment Video

Updated: Aug 14, 2025

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

Acupuncture combined with metformin for polycystic ovary syndrome: A protocol for systematic review and meta-analysis

Yanan Sun¹, Xiuping Liu², Qi Ding¹

¹Department of Gynecology and Obstetrics, The 980th Hospital of the Joint Logistic Support Force of PLA, China.

|January 10, 2023

Abstract

Background:

Polycystic ovary syndrome is an endocrine disorder that occurs mostly in women of reproductive age and has lifelong effects on their health.

Methods:

Randomized controlled clinical trials that met the inclusion criteria were screened by searching multiple databases. Relevant data were extracted, and meta-analysis was performed using Reviewer Manager 5.4.

Results:

The results of this study will be submitted to peer-reviewed journals.

Conclusion:

This study provides evidence for the efficacy and safety of the clinical application of acupuncture combined with metformin in the treatment of polycystic ovary syndrome.

More Related Videos

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Articles linked to this work by shared authors, journal, and citation graph.

FSCN1 Modulates Fatty Acid Metabolism and the Coordinated Activation of AKT/mTOR and p38 MAPK Pathways in Colorectal Cancer Cells.

Oncology research·2026

DELLA proteins enhance cadmium tolerance by coordinating redox protection and cadmium partitioning in Arabidopsis.

Planta·2026

Angiopep-2-functionalized Cu-Mn oxide nanoplatform for blood-brain barrier penetration and radiotherapy-enhanced cuproptosis in glioma therapy.

Biomedical materials (Bristol, England)·2026

Effects and mechanisms of Stauntonia brachyanthera Hand.-Mazz against Alzheimer's disease through network pharmacology and experimental validation.

Biochemical and biophysical research communications·2026

HOXC9 promotes cell proliferation and suppresses mitochondria-dependent apoptosis through the AKT/mTOR pathway in esophageal squamous cell carcinoma.

Molecular and cellular biochemistry·2026

PKCα-deficient mice show altered synaptic signaling and impaired fear extinction.

Neurobiology of stress·2026

See all related articles